Bayer suspends safety manager duo

Gibson, Jane
October 2006
ICIS Chemical Business;10/23/2006, Vol. 1 Issue 40, p8
Trade Publication
The article reports that Bayer Healthcare has suspended two unnamed pharmaceutical safety managers, blaming them for not sharing with the U.S. Food and Drug Administration negative information about the proteinase inhibitor Trasyol, used in open-heart surgery. At the same time, Bayer announced the appointment of an independent counsel to review the company's failure to disclose the information.


Related Articles

  • BAYER HEALTHCARE.  // Contract Pharma;Jul/Aug2013, Vol. 15 Issue 6, p91 

    The article profiles Bayer Healthcare, one of the 2013 top 20 pharmaceutical companies ranked based on the company's revenue in 2012. It states that the company pushed to achieve its 26% goal overall growth in pharmaceutical revenues between 2011 and 2014. It mentions that Bayer and partner...

  • Regulation and Risk Management. Wechsler, Jill // Applied Clinical Trials;Oct2003, Vol. 12 Issue 10, p20 

    Discusses the plans of the U.S. Food and Drug Administration (FDA) to rewrite rules governing electronic records to encourage risk-based regulatory approaches. Announcement of several policies related to the campaigns of the FDA to update good manufacturing practice requirements for human and...

  • Washington update. Wechsler, Jill // Formulary;Dec95, Vol. 30 Issue 12, p840 

    Examines the US Food and Drug Administration's (FDA) draft proposal calling for manufacturer drug efficacy and cost-effectiveness claims to be based on two adequate and well-controlled studies. Effect on manufacturer promotional practices particularly by companies linked to pharmacy benefit...

  • Understanding and Implementing A Risk-Based Approach to 21 CFR Part 11 Compliance. Gorban, Arik; Townsend, Kate // Pharmaceutical Technology;Jul2003, Vol. 27 Issue 7, p70 

    Discusses the U.S. Food and Drug Administration's risk-based approach to regulatory compliance for the pharmaceutical industry. Change in the agency's thinking towards pharmaceutical facility inspections and adherence to quality practices; Steps involved in implementing a risk-based approach to...

  • FDA Pilots New Quality Assessment System.  // Pharmaceutical Technology;Aug2005, Vol. 29 Issue 8, p20 

    Reports on the invitation of the U.S. Food and Drug Administration for several pharmaceutical companies to take part in a pilot program designed to develop guidance for a new quality assessment system. Requirements for companies participating in the program; Usefulness of the result in...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Jan2006, Vol. 41 Issue 1, p14 

    The article comments on how the Food and Drug Administration (FDA) block nonprescription sales of emergency contraceptive Plan B in the U.S. According to the Government Accountability Office in a report issued in November 2005, the decision not to approved Plan B for nonprescription sale was...

  • Manufacturers Face Shifting Priorities in the New Year. Wechsler, Jill // Pharmaceutical Technology North America;Jan2002, Vol. 26 Issue 1, p14 

    Reports on developments in the pharmaceutical industry in the U.S. Demand for critical medicines following the September 11 attacks; Passage of legislation regarding pharmaceutical regulations and price controls; Priorities of the Food and Drug Administration.

  • Assessing the impact of FDA reform. Hess, Glenn // Chemical Market Reporter;11/23/98, Vol. 254 Issue 21, pFR8 

    Focuses on the impact of new regulations passed by the United States Food and Drug Administration (FDA) governing pharmaceuticals on the pharmaceutical industry in the United States. Patients and families as the ultimate beneficiaries of the FDA reform legislation; Overview on the conditions...

  • FDA Initiative Will Enhance Drug Good Manufacturing Practices.  // FDA Consumer;Nov/Dec2002, Vol. 36 Issue 6, p4 

    Reports on an initiative by the U.S. Food and Drug Administration to enhance the regulation of drug manufacturing and product quality. Concerns about below-standard drug manufacturing practices; Suggestion that the initiative does not impede innovations in the drug industry.


Other Topics